MR Imaging Findings in Hepatic Encephalopathy

References

1. ↵
   Cordoba J, Blei AT. Hepatic encephalopathy. In: Shiff ER, Sorrell MF, Maddrey WC, eds. Shiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins;2003 :595–623
2. ↵
   Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification—final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716–21

   CrossRefPubMedWeb of Science
3. ↵
   Weissenborn K. Diagnosis of encephalopathy. Digestion 1998;59 (suppl 2):22–24

   CrossRefPubMedWeb of Science
4. Cadranel JF, Lebiez E, Di Martino V, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol 2001;96:515–18

   CrossRefPubMedWeb of Science
5. Joebges EM, Heidemann M, Schimke N, et al. Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation. J Hepatol 2003;38:273–80

   CrossRefPubMed
6. Krieger S, Jauss M, Jansen O, et al. Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. Gastroenterology 1996;111:147–55

   CrossRefPubMedWeb of Science
7. ↵
   Adams RD, Foley JM. The neurological disorder associated with liver disease. Res Publ Assoc Res Nerv Ment Dis 1953;32:198–237

   PubMed
8. ↵
   Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005;42 (suppl 1):S45–S53

   CrossRefPubMedWeb of Science
9. ↵
   Amodio P, Montagnese S, Gatta A, et al. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004;19:253–67

   CrossRefPubMedWeb of Science
10. ↵
    Weissenborn K, Ennen JC, Schomerus H, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768–73

    CrossRefPubMedWeb of Science
11. ↵
    Weissenborn K, Bokemeyer M, Ahl B, et al. Functional imaging of the brain in patients with liver cirrhosis. Metab Brain Dis 2004;19:269–80

    CrossRefPubMedWeb of Science
12. ↵
    Albrecht J, Jones EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neurol Sci 1999;170:138–46

    CrossRefPubMedWeb of Science
13. ↵
    Butterworth RF. The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996;16:235–44

    PubMedWeb of Science
14. ↵
    Hazell AS. Astrocytes and manganese neurotoxicity. Neurochem Int 2002;41:271–77

    CrossRefPubMedWeb of Science
15. Normandin L, Hazell AS. Manganese neurotoxicity: an update of pathophysiologic mechanisms. Metab Brain Dis 2002;17:375–87

    CrossRefPubMedWeb of Science
16. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002;17:221–27

    CrossRefPubMedWeb of Science
17. ↵
    Rao KV, Norenberg MD. Cerebral energy metabolism in hepatic encephalopathy and hyperammonemia. Metab Brain Dis 2001;16:67–78

    CrossRefPubMed
18. ↵
    Papavasiliou PS, Miller ST, Cotzias GC. Role of liver in regulating distribution and excretion of manganese. Am J Physiol 1966;211:211–16

    FREE Full Text
19. ↵
    Stallings WC, Metzger AL, Pattridge KA, et al. Structure-function relationships in iron and manganese superoxide dismutases. Free Radic Res Commun 1991;12 –13(Pt 1):259–68

    CrossRefPubMed
20. Wedler FC, Tom R. Interactions of Mn (II) with mammalian glutamine synthetase. In: Schramm VL, Wedler FC, eds. Manganese in Metabolism and Enzyme Function. New York: Academic Press;1986 :221–38
21. ↵
    Bentle LA, Lardy HA. Interaction of anions and divalent metal ions with phosphoenolpyruvate carboxykinase. J Biol Chem 1976;251:2916–21

    Abstract/FREE Full Text
22. ↵
    Couper J. On the effects of black oxide of manganese when inhaled into the lungs. Br Ann Med Pharmacol 1837;1:41–42
23. ↵
    Mena I, Marin O, Fuenzalida S, et al. Chronic manganese poisoning: clinical picture and manganese turnover. Neurology 1967;17:128–36

    FREE Full Text
24. Barbeau A. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). Neurotoxicology 1984;5:13–35

    PubMedWeb of Science
25. ↵
    Emara AM, el-Ghawabi SH, Madkour OI, et al. Chronic manganese poisoning in the dry battery industry. Br J Ind Med 1971;28:78–82

    PubMedWeb of Science
26. ↵
    Yamada M, Ohno S, Okayasu I, et al. Chronic manganese poisoning: a neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol 1986;70:273–78

    CrossRefPubMed
27. Olanow CW, Good PF, Shinotoh H, et al. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 1996;46:492–98

    Abstract/FREE Full Text
28. ↵
    Spadoni F, Stefani A, Morello M, et al. Selective vulnerability of pallidal neurons in the early phases of manganese intoxication. Exp Brain Res 2000;135:544–51

    CrossRefPubMedWeb of Science
29. ↵
    Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999;117:640–44

    CrossRefPubMedWeb of Science
30. ↵
    Burkhard PR, Delavelle J, Pasquier RD, et al. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol 2003;60:521–28

    CrossRefPubMedWeb of Science
31. ↵
    Olanow CW. Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci 2004;1012:209–23

    CrossRefPubMedWeb of Science
32. Shulman LM, Minagar A, Weiner WJ. Reversal of parkinsonism following liver transplantation. Neurology 2003;60:519

    FREE Full Text
33. Calne D, Chu N, Huang C, et al. Manganism and idiopathic parkinsonism: similarities and differences. Neurology 1994;44:1583–86

    FREE Full Text
34. ↵
    Klos KJ, Ahlskog JE, Josephs KA, et al. Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. Arch Neurol 2005;62:1385–90

    CrossRefPubMedWeb of Science
35. ↵
    Morgan MY. Noninvasive neuroinvestigation in liver disease. Semin Liver Dis 1996;16:293–314

    PubMed
36. ↵
    Pujol A, Pujol J, Graus F, et al. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993;43:65–69

    Abstract/FREE Full Text
37. ↵
    Krieger S, Jauss M, Jansen O, et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. J Hepatol 1997;27:121–26

    CrossRefPubMedWeb of Science
38. ↵
    Matsumoto S, Mori H, Yoshioka K, et al. Effects of portal-systemic shunt embolization on the basal ganglia: MRI. Neuroradiology 1997;39:326–28

    CrossRefPubMed
39. ↵
    Butterworth RF, Spahr L, Fontaine S, et al. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab Brain Dis 1995;10:259–67

    CrossRefPubMedWeb of Science
40. ↵
    Spahr L, Butterworth RF, Fontaine S, et al. Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996;24:1116–20

    CrossRefPubMedWeb of Science
41. Hauser RA, Zesiewicz TA, Rosemurgy AS, et al. Manganese intoxication and chronic liver failure. Ann Neurol 1994;36:871–75

    CrossRefPubMedWeb of Science
42. ↵
    Katsuragi T, Iseki E, Kosaka K, et al. Cerebrospinal fluid manganese concentrations in patients with symmetric pallidal hyperintensities on T1 weighted MRI. J Neurol Neurosurg Psychiatry 1999;66:551–52

    FREE Full Text
43. ↵
    Pomier-Layrargues G, Spahr L, Butterworth RF. Increased manganese concentrations in pallidum of cirrhotic patients. Lancet 1995;345:735

    PubMed
44. ↵
    Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270–74

    CrossRefPubMedWeb of Science
45. ↵
    Mirowitz SA, Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology 1991;181:117–20

    PubMedWeb of Science
46. Nagatomo S, Umehara F, Hanada K, et al. Manganese intoxication during total parenteral nutrition: report of two cases and review of the literature. J Neurol Sci 1999;162:102–05

    CrossRefPubMedWeb of Science
47. ↵
    Mirowitz SA, Westrich TG. Basal ganglia signal intensity alterations: reversal after discontinuation of parenteral manganese administration. Radiology 1992;185:535–36

    PubMedWeb of Science
48. ↵
    Ejima A, Imamura T, Nakamura S, et al. Manganese intoxication during total parenteral nutrition. Lancet 1992;339:426

    CrossRefPubMedWeb of Science
49. ↵
    Josephs KA, Ahlskog JE, Klos KJ, et al. Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. Neurology 2005;64:2033–39

    Abstract/FREE Full Text
50. ↵
    Nolte W, Wiltfang J, Schindler CG, et al. Bright basal ganglia in T1-weighted magnetic resonance images are frequent in patients with portal vein thrombosis without liver cirrhosis and not suggestive of hepatic encephalopathy. J Hepatol 1998;29:443–49

    CrossRefPubMed
51. Mínguez B, García-Pagán JC, Bosch J, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology 2006;43:707–14

    CrossRefPubMedWeb of Science
52. ↵
    Ortiz M, Córdoba J, Alonso J, et al. Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts. J Hepatol 2004;40:552–57

    CrossRefPubMed
53. ↵
    Devenyi AG, Barron TF, Mamourian AC. Dystonia, hyperintense basal ganglia, and high whole blood manganese levels in Alagille's syndrome. Gastroenterology 1994;106:1068–71

    PubMedWeb of Science
54. ↵
    Lai PH, Chen C, Liang HL, et al. Hyperintense basal ganglia on T1-weighted MR imaging. AJR Am J Roentgenol 1999;172:1109–15

    PubMedWeb of Science
55. ↵
    Lockwood AH, Weissenborn K, Butterworth RF. An image of the brain in patients with liver disease. Curr Opin Neurol 1997;10:525–33

    PubMed
56. ↵
    Weissenborn K, Ehrenheim C, Hori A, et al. Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation. Metab Brain Dis 1995;10:219–31

    CrossRefPubMedWeb of Science
57. ↵
    Córdoba J, Alonso J, Rovira A, et al. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001;35:598–604

    CrossRefPubMedWeb of Science
58. ↵
    Cordoba J, Olive G, Alonso J, et al. Improvement of magnetic resonance spectroscopic abnormalities but not pallidal hyperintensity followed amelioration of hepatic encephalopathy after occlusion of a large spleno-renal shunt. J Hepatol 2001;34:176–78

    PubMed
59. ↵
    Naegele T, Grodd W, Viebahn R, et al. MR imaging and 1H spectroscopy of brain metabolites in hepatic encephalopathy: time-course of renormalization after liver transplantation. Radiology 2000;216:683–91

    PubMedWeb of Science
60. ↵
    Cooper JL, Plum F. Biochemistry and physiology of brain ammonia. Physiol Rev 1987;67:440–519

    FREE Full Text
61. ↵
    Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991;11:337–41

    PubMedWeb of Science
62. ↵
    Norenberg MD. Astroglial dysfunction in hepatic encephalopathy. Metab Brain Dis 1998;13:319–35

    CrossRefPubMedWeb of Science
63. ↵
    Martinez-Hernandez A, Bell KP, Norenberg MD. Glutamine synthetase: glial localization in brain. Science 1977;195:1356–85

    Abstract/FREE Full Text
64. ↵
    Donovan JP, Shafer DF, Shaw BW Jr, et al. Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet 1998;351:719–21

    PubMed
65. ↵
    McManus ML, Churchwell KB, Strange K. Regulation of cell volume in health and disease. N Engl J Med 1995;333:1260–66

    CrossRefPubMedWeb of Science
66. ↵
    Butterworth RF, Giguere JF, Michaud J, et al. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987;6:1–12

    CrossRefPubMedWeb of Science
67. ↵
    Haussinger D, Laubenberger J, Dahl S, et al. Proton magnetic resonance spectroscopy studies on human brain myoinositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994;107:1475–80

    CrossRefPubMedWeb of Science
68. ↵
    Lee JH, Seo DW, Lee Y, et al. Proton magnetic resonance spectroscopy (1H-MRS) findings for the brain in patients with liver cirrhosis reflect the hepatic functional reserve. Am J Gastroenterol 1999;94:2206–13

    CrossRefPubMed
69. Laubenberger J, Häussinger D, Bayer S, et al. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997;112:1610–16

    CrossRefPubMedWeb of Science
70. Geissler A, Lock G, Fründ R, et al. Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging. Hepatology 1997;25:48–54

    CrossRefPubMedWeb of Science
71. Ross BD, Jacobson S, Villamil F, et al. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology 1994;193:457–63

    PubMedWeb of Science
72. Kreis R, Ross BD, Farrow NA, et al. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 1992;182:19–27

    PubMedWeb of Science
73. ↵
    Köstler H. Proton magnetic resonance spectroscopy in portal-systemic encephalopathy. Metab Brain Dis 1998;13:291–301

    CrossRefPubMed
74. ↵
    Córdoba J, Gottstein J, Blei AT. Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. Hepatology 1996;24:919–23

    PubMedWeb of Science
75. ↵
    Thomas MA, Huda A, Guze B, et al. Cerebral 1H MR spectroscopy and neurophsychologic status of patients with hepatic encephalopathy. AJR Am J Roentgenol 1998;171:1123–30

    PubMed
76. ↵
    Cordoba J, Raguer N, Flavia M, et al. T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology 2003;38:1026–33

    CrossRefPubMed
77. ↵
    Córdoba J, Blei AT. Brain edema and hepatic encephalopathy. Semin Liver Dis 1996;16:271–80

    PubMed
78. ↵
    Haussinge D, Kircheis G, Fischer R, et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000;32:1035–38

    CrossRefPubMedWeb of Science
79. ↵
    Jalan R, Dabos K, Redhead DN, et al. Elevation of intracranial pressure following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 1997;27:928–33

    CrossRefPubMed
80. ↵
    Swain MS, Blei AT, Butterworth RF, et al. Intracellular pH rises in astrocytes swell after portocaval anastomosis in rats. Am J Physiol 1991;261:R1491–96

    PubMed
81. ↵
    Norenberg MD. The astrocyte in liver disease. In: Fedoroff S, Hertz L, eds. Advances in Cellular Neurobiology. New York: Academic Press;1981 :303–52
82. ↵
    Iwasa M, Kinosada Y, Nakatsuka A, et al. Magnetization transfer contrast of various regions of the brain in liver cirrhosis. AJNR Am J Neuroradiol 1999;20:652–54

    Abstract/FREE Full Text
83. ↵
    Rovira A, Grivé E, Pedraza S, et al. Magnetization transfer ratio values and proton MR spectroscopy of normal-appearing cerebral white matter in patients with liver cirrhosis. AJNR Am J Neuroradiol 2001;22:1137–42

    Abstract/FREE Full Text
84. ↵
    Rovira A, Cordoba J, Sanpedro F, et al. Normalization of T2 signal abnormalities in hemispheric white matter with liver transplant. Neurology 2002;9:335–41
85. ↵
    Lodi R, Tonon C, Stracciari A, et al. Diffusion MRI shows increased water apparent diffusion coefficient in the brains of cirrhotics. Neurology 2004;62:762–66

    Abstract/FREE Full Text
86. ↵
    Kale RA, Gupta RK, Saraswat VA, et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 2006;43:698–706

    CrossRefPubMedWeb of Science
87. ↵
    Wolf SD, Balaban RS. Magnetization transfer imaging: practical aspects and clinical applications. Radiology 1994;192:593–99

    PubMedWeb of Science
88. ↵
    Dousset V, Grossman RI, Ramer KN, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 1992;182:483–91

    PubMedWeb of Science
89. Dousset V, Brochet B, Vital A, et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR Am J Neuroradiol 1995;16:225–31

    Abstract/FREE Full Text
90. Dousset V, Armand JP, Lacoste D, et al. Magnetization transfer study of HIV encephalitis and progressive multifocal leukoencephalopathy. AJNR Am J Neuroradiol 1997;18:895–901

    Abstract/FREE Full Text
91. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675–83

    Abstract
92. ↵
    Rovira A, Alonso J, Cucurella G, et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. AJNR Am J Neuroradiol 1999;20:1939–45

    Abstract/FREE Full Text
93. ↵
    Iwasa M, Kinosada Y, Watanabe S, et al. Hepatic cirrhosis: magnetization transfer contrast in globus pallidus. Neuroradiology 1998;40:145–49

    CrossRefPubMed
94. ↵
    Lee YC, Markus R, Hughes A. MRI in ALS: corticospinal tract hyperintensity. Neurology 2003;61:1600

    FREE Full Text
95. ↵
    Rydberg JN, Hammond CA, Grimm RC, et al. Initial experience in MR imaging of the brain with a fast fluid-attenuated inversion-recovery pulse sequence. Radiology 1994;193:173–80

    PubMedWeb of Science
96. ↵
    Mirowitz S, Sartor K, Gado M, et al. Focal signal-intensity variations in the posterior internal capsule: normal MR findings and distinction from pathological findings. Radiology 1989;172:535–39

    PubMed
97. ↵
    Gawne-Cain ML, Silver NC, Moseley IF, et al. Fast FLAIR of the brain: the range of appearances in normal subjects and its application to quantification of white-matter disease. Neuroradiology 1997;39:243–49

    CrossRefPubMedWeb of Science
98. ↵
    Patel N, White S, Dhanjal NS, et al. Changes in brain size in hepatic encephalopathy: a coregistered MRI study. Metab Brain Dis 2004;19:431–45

    CrossRefPubMed
99. ↵
    Sarchielli P, Pelliccioli GP, Tarducci R, et al. Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001;43:189–97

    CrossRefPubMedWeb of Science
100. ↵
     Shaw PJ, Eggett CJ. Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J Neurol 2000;247:17–27

     CrossRef
101. Vogels BA, Maas MA, Daalhuisen J, et al. Memantine, an non-competitive NMDA-receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 1997;25:820–27

     CrossRefPubMedWeb of Science
102. ↵
     Knecht K, Michalak A, Rose C, et al. Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute liver failure. Neurosci Lett 1997;229:201–03

     CrossRefPubMedWeb of Science
103. ↵
     Weber M, Eisen AA. Magnetic stimulation of the central and peripheral nervous systems. Muscle Nerve 2002;25:160–75

     CrossRefPubMedWeb of Science
104. ↵
     de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study—The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001;70:9–14

     Abstract/FREE Full Text
105. ↵
     Mínguez B, Rovira A, Alonso J, et al. Decrease in the volume of white matter lesions with improvement of hepatic encephalopathy. AJNR Am J Neuroradiol 2007;28:1499–500

     Abstract/FREE Full Text
106. ↵
     Rovira A, Mínguez B, Córdoba J, et al. Decreased white matter lesion volume and improved cognitive function following liver transplantation. Hepatology 2007;46:1485–90

     CrossRefPubMed
107. ↵
     Schmidt R, Enzinger C, Ropele S, et al, for the Austrian Stroke Prevention Study. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003;361:2046–48

     CrossRefPubMedWeb of Science
108. Taylor WD, MacFall JR, Provenzale JM, et al. Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. AJR Am J Roentgenol 2003;181:571–76

     CrossRefPubMedWeb of Science
109. ↵
     Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005;112:1644–50. Epub 2005 Sep 6

     Abstract/FREE Full Text
110. ↵
     Miese F, Kircheis G, Wittsack HJ, et al. 1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy. AJNR Am J Neuroradiol 2006;27:1019–26

     Abstract/FREE Full Text
111. ↵
     Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology 2000;217:331–45

     CrossRefPubMedWeb of Science
112. ↵
     Ziylan YZ, Uzum G, Bernard G, et al. Changes in the permeability of the blood-brain barrier in acute hyperammonemia: effect of dexamethasone. Mol Chem Neuropathol 1993;20:203–18

     PubMed
113. ↵
     Hazell AS, Normandin L, Norenberg MD, et al. Alzheimer type II astrocytic changes following sub-acute exposure to manganese and its prevention by antioxidant treatment. Neurosci Lett 2006;396:167–71

     CrossRefPubMedWeb of Science
114. ↵
     Sobel RA, DeArmond SJ, Forno LS, et al. Glial fibrillary acidic protein in hepatic encephalopathy: an immunohistochemical study. J Neuropathol Exp Neurol 1981;40:625–32

     CrossRefPubMed
115. ↵
     Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 2000;25:1439–51

     CrossRefPubMedWeb of Science
116. ↵
     Chen KC, Nicholson C. Changes in brain cell shape create residual extracellular space volume and explain tortuosity behavior during osmotic challenge. Proc Natl Acad Sci U S A 2000;97:8306–11

     Abstract/FREE Full Text
117. ↵
     Ranjan P, Mishra AM, Kale R, et al. Cytotoxic edema is responsible for raised intracranial pressure in fulminant hepatic failure: in vivo demonstration using diffusion-weighted MRI in human subjects. Metab Brain Dis 2005;20:181–92

     CrossRefPubMedWeb of Science